Evidence-Based Biosafety: a Review of the Principles and Effectiveness of Microbiological Containment Measures
暂无分享,去创建一个
[1] Z. Memish,et al. Brucellosis in laboratory workers at a Saudi Arabian hospital. , 2001, American journal of infection control.
[2] Peter Neubauer,et al. An expression vector system providing plasmid stability and conditional suicide of plasmid-containing cells , 1992, Applied Microbiology and Biotechnology.
[3] D. Duan,et al. Adeno-associated virus vectors , 1992 .
[4] T. Komori,et al. [Current biosafety in clinical laboratories in Japan: report of questionnaires' data obtained from clinical laboratory personnel in Japan]. , 2007, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases.
[5] M. Kortepeter,et al. Risk of occupationally acquired illnesses from biological threat agents in unvaccinated laboratory workers. , 2004, Biosecurity and bioterrorism : biodefense strategy, practice, and science.
[6] I. Salkin. Laboratory-Acquired Meningococcal Disease—United States, 2000 , 2002 .
[7] P. Andersen,et al. The success and failure of BCG — implications for a novel tuberculosis vaccine , 2005, Nature Reviews Microbiology.
[8] D. Normile. Infectious diseases. Second lab accident fuels fears about SARS. , 2004, Science.
[9] N. Moussatché,et al. Accidental Infection of Laboratory Worker with Vaccinia , 2003, Emerging Infectious Diseases.
[10] J. Waner,et al. Laboratory-acquired vaccinia infection. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[11] S. Isaacs. Working Safely with Vaccinia Virus , 2004 .
[12] Tiina Reponen,et al. Do N95 respirators provide 95% protection level against airborne viruses, and how adequate are surgical masks? , 2006, American journal of infection control.
[13] J. Hansen,et al. Safe sorting of GFP-transduced live cells for subsequent culture using a modified FACS vantage. , 1999, Cytometry.
[14] F. Meinhardt,et al. Strain development in Bacillus licheniformis: construction of biologically contained mutants deficient in sporulation and DNA repair. , 2005, Journal of biotechnology.
[15] D. Hunt,et al. Biological safety : principles and practices , 2006 .
[16] D. Fleming,et al. Laboratory-acquired meningococcal disease--United States, 2000. , 2002, MMWR. Morbidity and mortality weekly report.
[17] G. B. Phillips,et al. Laboratory design for microbiological safety. , 1967, Applied microbiology.
[18] Titenko Am. [Marburg hemorrhagic fever]. , 1991, Zhurnal mikrobiologii, epidemiologii, i immunobiologii.
[19] F. Siñeriz,et al. The Argentine Experience in Enhancing Biosafety through Good Laboratory Practices , 2006 .
[20] Pablo Yagupsky, Nechama Peled, Klaris Riesenberg,. Exposure of Hospital Personnel to Brucella melitensis and Occurrence of Laboratory-acquired Disease in an Endemic Area , 2000 .
[21] C. D. Miller,et al. A twenty-five year review of laboratory-acquired human infections at the National Animal Disease Center. , 1987, American Industrial Hygiene Association journal.
[22] S. Blower,et al. Theory versus Data: How to Calculate R0? , 2007, PloS one.
[23] A. Seidler,et al. Review of Epidemiological Studies on the Occupational Risk of Tuberculosis in Low-Incidence Areas , 2005, Respiration.
[24] L R Murphy,et al. Compliance with universal precautions among health care workers at three regional hospitals. , 1996, American journal of infection control.
[25] M. Singer,et al. Asilomar conference on recombinant DNA molecules. , 1975, Science.
[26] R. Salmon,et al. Vero cytotoxin‐producing Escherichia coli O157 in beefburgers linked to an outbreak of diarrhoea, haemorrhagic colitis and haemolytic uraemic syndrome in Britain , 1994, Letters in applied microbiology.
[27] E. Bernasconi,et al. Brucellosis: An occupational hazard for medical laboratory personnel. Report of five cases , 2005, Infection.
[28] K. Killeen,et al. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. , 1999, Vaccine.
[29] L. Steidler,et al. Live genetically modified bacteria as drug delivery tools: at the doorstep of a new pharmacology? , 2004, Expert opinion on biological therapy.
[30] Caroline C. Johnson,et al. Ocular Vaccinia Infection in Laboratory Worker, Philadelphia, 2004 , 2006, Emerging infectious diseases.
[31] D. O'reilly,et al. Baculovirus expression vectors: a laboratory manual. , 1992 .
[32] R Osborne,et al. Performance of open‐fronted microbiological safety cabinets: the value of operator protection tests during routine servicing , 1999, Journal of applied microbiology.
[33] B. Wallace,et al. Laboratory-acquired Brucellosis , 2004, Emerging infectious diseases.
[34] E. Paoletti. Applications of pox virus vectors to vaccination: an update. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[35] M. S. Barbeito,et al. Containment of microbial aerosols in a microbiological safety cabinet. , 1968, Applied microbiology.
[36] D Walker,et al. A survey of infections in United Kingdom laboratories, 1994-1995. , 1999, Journal of clinical pathology.
[37] R. Hanson,et al. Arbovirus infections of laboratory workers. Extent of problem emphasizes the need for more effective measures to reduce hazards. , 1967, Science.
[38] J. Ring,et al. Laboratory acquired infection with recombinant vaccinia virus containing an immunomodulating construct. , 2003, The Journal of investigative dermatology.
[39] Laura H. Kahn. Biodefense research: can secrecy and safety coexist? , 2004, Biosecurity and bioterrorism : biodefense strategy, practice, and science.
[40] Smallpox and Its Eradication , 1988 .
[41] W. Lim,et al. Laboratory containment of SARS virus. , 2006, Annals of the Academy of Medicine, Singapore.
[42] A. G. Wedum. II. AIRBORNE INFECTION IN THE LABORATORY. , 1964, American journal of public health and the nation's health.
[43] S. Gorbach. Recombinant DNA: an infectious disease perspective. , 1978, The Journal of infectious diseases.
[44] A. G. Wedum. Control of laboratory airborne infection. , 1961, Bacteriological reviews.
[45] H. Feldmann,et al. Emerging and reemerging of filoviruses. , 1996, Archives of virology. Supplementum.
[46] Arturo Casadevall,et al. Host-Pathogen Interactions: Redefining the Basic Concepts of Virulence and Pathogenicity , 1999, Infection and Immunity.
[47] Hao Wang,et al. Biosafety Level 3 Laboratory for Autopsies of Patients with Severe Acute Respiratory Syndrome: Principles, Practices, and Prospects , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[48] Marburg hemorrhagic fever , 2020, Definitions.
[49] D. Normile. SARS Experts Want Labs to Improve Safety Practices , 2003, Science.
[50] J. Trempe,et al. A helper virus-free packaging system for recombinant adeno-associated virus vectors. , 1999, Gene.
[51] N. Grist,et al. Infections in British clinical laboratories, 1988-1989. , 1991, Journal of clinical pathology.
[52] Kennedy Da,et al. Microbiological safety cabinets: selection, installation, testing and use. , 2000 .
[53] Heinz Feldmann,et al. Ebola virus: from discovery to vaccine , 2003, Nature Reviews Immunology.
[54] S. Knudsen,et al. Development and testing of improved suicide functions for biological containment of bacteria , 1995, Applied and environmental microbiology.
[55] H. Bourne,et al. Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease. , 1970, The American journal of tropical medicine and hygiene.
[56] K L Keatley. Controversy over genetically modified organisms: the governing laws and regulations. , 2000, Quality assurance.
[57] R. Koup,et al. Viable infectious cell sorting in a BSL-3 facility. , 2004, Methods in molecular biology.
[58] Nikiforov Vv,et al. A case of a laboratory infection with Marburg fever , 1994 .
[59] W. Emmett Barkley,et al. Biosafety in microbiological and biomedical laboratories , 1984 .
[60] M. Poznansky,et al. The development of a gene therapy , 1997, International journal of STD & AIDS.
[61] R. Rico-Hesse,et al. New arenavirus isolated in Brazil , 1994, The Lancet.
[62] R. Good,et al. Biosafety in the clinical mycobacteriology laboratory. , 1996, Clinics in laboratory medicine.
[63] H. Smith. Is it safe to use Escherichia coli K12 in recombinant DNA experiments? , 1978, The Journal of infectious diseases.
[64] Samuel I. Miller,et al. Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo , 1999, Nature Biotechnology.
[65] D. Simpson,et al. Fatal human disease from vervet monkeys. , 1967, Lancet.
[66] J. Lanser,et al. A Comparative Study of Methods To Validate Formaldehyde Decontamination of Biological Safety Cabinets , 1999, Applied and Environmental Microbiology.
[67] David E. Swayne,et al. Characterization of the Reconstructed 1918 Spanish Influenza Pandemic Virus , 2005, Science.
[68] J. Sejvar,et al. Assessing the Risk of Laboratory-Acquired Meningococcal Disease , 2005, Journal of Clinical Microbiology.
[69] D. Ashford,et al. Descriptive profile of tuberculin skin testing programs and laboratory-acquired tuberculosis infections in public health laboratories , 1997, Journal of clinical microbiology.
[70] Christopher Dye,et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. , 2003, Archives of internal medicine.
[71] Ingrid Schmid,et al. Biosafety concerns for shared flow cytometry core facilities , 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[72] K. Killeen,et al. Advances in the development of bacterial vector technology , 2003, Expert review of vaccines.
[73] Jonathan Y. Richmond,et al. Biosafety in microbiological and biomedical laboratories , 1999 .
[74] G. Lloyd,et al. A case of Ebola virus infection. , 1977, British medical journal.
[75] Diane O. Fleming,et al. Epidemiology of laboratory-associated infections. , 2006 .
[76] L. Bermudez,et al. In vivo efficacy of phage therapy for Mycobacterium avium infection as delivered by a nonvirulent mycobacterium. , 2006, Microbial drug resistance.
[77] S. Cryz,et al. Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity. , 2000, Vaccine.
[78] A. G. Wedum. Bacteriological safety. , 1953, American journal of public health and the nation's health.
[79] A. G. Wedum. LABORATORY SAFETY IN RESEARCH WITH INFECTIOUS AEROSOLS. , 1964, Public health reports.
[80] G. Dougan,et al. Salmonella typhi and S typhimurium derivatives harbouring deletions in aromatic biosynthesis and Salmonella Pathogenicity Island-2 (SPI-2) genes as vaccines and vectors. , 2003, Vaccine.
[81] L. Naldini,et al. Interaction of Human Immunodeficiency Virus-Derived Vectors with Wild-Type Virus in Transduced Cells , 1999, Journal of Virology.
[82] E. Bouza,et al. Laboratory-acquired brucellosis: a Spanish national survey. , 2005, The Journal of hospital infection.
[83] D L Sewell,et al. Laboratory-associated infections and biosafety , 1995, Clinical microbiology reviews.
[84] V. V. Nikiforov,et al. [A case of a laboratory infection with Marburg fever]. , 1994, Zhurnal mikrobiologii, epidemiologii, i immunobiologii.
[85] A. Ramsay,et al. Expression of Mouse Interleukin-4 by a Recombinant Ectromelia Virus Suppresses Cytolytic Lymphocyte Responses and Overcomes Genetic Resistance to Mousepox , 2001, Journal of Virology.
[86] H. Pandha,et al. Novel strains of Salmonella typhimurium as potential vectors for gene delivery. , 2004, FEMS microbiology letters.
[87] S. Bavari,et al. Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[88] Dawn P. Wooley,et al. Risk assessment of biological hazards. , 2006 .
[89] V. Kiermer,et al. Development of a sensitive assay for detection of replication-competent recombinant lentivirus in large-scale HIV-based vector preparations. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.
[90] M. S. Barbeito,et al. Microbiological hazard from the exhaust of a high-vacuum sterilizer , 1976, Applied and environmental microbiology.
[91] J. Gonzalez,et al. Brief report: treatment of a laboratory-acquired Sabiá virus infection. , 1995, The New England journal of medicine.
[92] Karen K Mortland,et al. Biosafety considerations in laboratory design. , 2003, Clinical leadership & management review : the journal of CLMA.
[93] J. Riou,et al. Enzyme electrophoresis, sero- and subtyping, and outer membrane protein characterization of two Neisseria meningitidis strains involved in laboratory-acquired infections , 1994, Journal of clinical microbiology.
[94] G. B. Phillips,et al. Laboratory design for study of infectious disease. , 1956, American journal of public health and the nation's health.
[95] M. Levine,et al. Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system , 1997, Infection and immunity.
[96] A. Giordano,et al. Gene Transfer Technology in Therapy: Current Applications and Future Goals , 1999, The oncologist.
[97] Second Lab Accident Fuels Fears About SARS , 2004, Science.
[98] D. A. Dotson,et al. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. , 2001, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[99] S. Zansky,et al. Four Laboratory-Associated Cases of Infection with Escherichia coli O157:H7 , 2005, Journal of Clinical Microbiology.
[100] B. Moss. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[101] G. B. Phillips. Microbiological hazards in the laboratory—Part one—Control , 1965 .
[102] D. Scherman,et al. A new DNA vehicle for nonviral gene delivery: supercoiled minicircle , 1997, Gene Therapy.
[103] J. Piškur,et al. Bacterial Toxin-Antitoxin Gene System as Containment Control in Yeast Cells , 2000, Applied and Environmental Microbiology.
[104] J. Kaiser. Accidents Spur a Closer Look at Risks at Biodefense Labs , 2007, Science.
[105] R. Curtiss,et al. Biological containment and cloning vector transmissibility. , 1978, The Journal of infectious diseases.
[106] O. Käppeli,et al. The science and intricacy of environmental safety evaluations. , 1997, Trends in biotechnology.
[107] Mario Roederer,et al. Measuring containment of viable infectious cell sorting in high‐velocity cell sorters , 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[108] I Schmid,et al. Biosafety considerations for flow cytometric analysis of human immunodeficiency virus-infected samples. , 1999, Cytometry.
[109] J. Modlin,et al. Vaccinia (Smallpox) Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001 , 2001 .
[110] L. Hovelius,et al. Report of Five Cases , 1977 .
[111] R. Samulski. Adeno-associated Viral Vectors , 1995 .
[112] E. Gandsman,et al. Sabia virus incident at Yale University. , 1997, American Industrial Hygiene Association journal.
[113] G. Kochs,et al. Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx1 resistance gene , 2007, Proceedings of the National Academy of Sciences.
[114] Erik Remaut,et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[115] R. Pike. Past and present hazards of working with infectious agents. , 1978, Archives of pathology & laboratory medicine.
[116] Raymond P. Clark. Standards for safety cabinets , 1997, Nature.
[117] H. Bouwer,et al. Pathogenicity and Immunogenicity of aListeria monocytogenes Strain That Requiresd-Alanine for Growth , 1998, Infection and Immunity.
[118] Jeff F. Miller,et al. Safety and Shedding of an Attenuated Strain of Listeria monocytogenes with a Deletion of actA/plcB in Adult Volunteers: a Dose Escalation Study of Oral Inoculation , 2002, Infection and Immunity.
[119] R. Kruse. Potential aerogenic laboratory hazards of Cocidioides immitis. , 1962, American journal of clinical pathology.
[120] E. V. Sargent,et al. Use of personal protective equipment for respiratory protection. , 2003, ILAR journal.
[121] C. H. Nelson,et al. Risk Perception, Behavior, and Consumer Response to Genetically Modified Organisms , 2001 .
[122] J. Glorioso,et al. 8 Gene-transfer Tool: Herpes Simplex Virus Vectors , 1999 .
[123] Thomas A. Kost,et al. Biosafety and Viral Gene Transfer Vectors , 2006 .
[124] Z. Debyser. Biosafety of lentiviral vectors. , 2003, Current gene therapy.
[125] W. Goebel,et al. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes , 1998, Nature Biotechnology.
[126] B. Herwaldt. Laboratory-Acquired Parasitic Infections from Accidental Exposures , 2001, Clinical Microbiology Reviews.
[127] J. Frame,et al. Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. , 1970, The American journal of tropical medicine and hygiene.
[128] N. Andrews,et al. Risk of laboratory-acquired meningococcal disease. , 2001, The Journal of hospital infection.
[129] R. Pike,et al. Laboratory-associated infections: incidence, fatalities, causes, and prevention. , 1979, Annual review of microbiology.
[130] R. Pike,et al. Survey of laboratory-acquired infections. , 1951, American journal of public health and the nation's health.
[131] Ingrid Schmid,et al. International Society for Analytical Cytology Biosafety Standard for Sorting of Unfixed Cells , 2007, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[132] Edward Elton,et al. The Effect of Microbiological Containment Systems on Dexterity , 2007, Journal of occupational and environmental hygiene.
[133] K. Riesenberg,et al. Exposure of hospital personnel to Brucella melitensis and occurrence of laboratory-acquired disease in an endemic area. , 2000, Scandinavian journal of infectious diseases.
[134] R. Pike,et al. Laboratory-associated infections: summary and analysis of 3921 cases. , 1976, Health laboratory science.
[135] N. de Wind,et al. Mutagenesis and characterization of a 41-kilobase-pair region of the pseudorabies virus genome: transcription map, search for virulence genes, and comparison with homologs of herpes simplex virus type 1. , 1994, Virology.
[136] A. Voss,et al. Laboratory diagnosis and biosafety issues of biological warfare agents. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[137] Jean Paul Remon,et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10 , 2003, Nature Biotechnology.
[138] M. First,et al. Effects of airflow rates and operator activity on containment of bacterial aerosols in a class II safety cabinet , 1984, Applied and environmental microbiology.
[139] Mengji Lu,et al. Improving the biosafety of cell sorting by adaptation of a cell sorting system to a biosafety cabinet , 2005, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[140] B. Moss,et al. Accidental human vaccination with vaccinia virus expressing nucleoprotein gene , 1986, Nature.
[141] D. Henderson,et al. Potential for laboratory exposures to biohazardous agents found in blood. , 1990, American journal of public health.
[142] P. Openshaw,et al. Accidental infection of laboratory worker with recombinant vaccinia virus , 1991, The Lancet.
[143] T. Dull,et al. Large‐scale manufacturing of safe and efficient retrovirus packaging lines for use in immunotherapy protocols , 1999 .
[144] T. Kimman,et al. Non-transmissible pseudorabies virus gp50 mutants: a new generation of safe live vaccines. , 1994, Vaccine.
[145] Christopher W. Wong,et al. Laboratory-acquired severe acute respiratory syndrome. , 2004, The New England journal of medicine.
[146] J. Coia. Nosocomial and laboratory-acquired infection with Escherichia coli O157. , 1998, The Journal of hospital infection.
[147] Hidekazu Nishimura,et al. Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus , 2004, Nature.
[148] A. K. Hansen,et al. Marburg and Ebola virus infections in laboratory non-human primates: a literature review. , 2000, Comparative medicine.